SCOPUS 정보 검색 플랫폼

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 26-27

Biomarkers in clinical drug development

(1) Gobburu, J V S a

a CENTER FOR DRUG EVALUATION AND RESEARCH (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ARGATROBAN; BIOLOGICAL MARKER; BUSULFAN; CARVEDILOL; CREATININE; CYCLOSPORIN; GLUCOSE; PIPERACILLIN; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID; SOTALOL; TAZOBACTAM; WARFARIN; ZOLEDRONIC ACID;

BONE DENSITY; DECISION MAKING; DISEASE MARKER; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG RELEASE; DRUG RESEARCH; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; BIOLOGICAL MARKERS; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 67650624058 PISSN: 00099236 EISSN: 15326535 Source Type: Journal
DOI: 10.1038/clpt.2009.57 Document Type: Note

Times cited : (25)

References (9)

1
- 67650604373
- The value, qualification, and regulatory use of surrogate end points in drug development
- Lathia CD et al. The value, qualification, and regulatory use of surrogate end points in drug development. Clin. Pharmacol. Ther. 86, 32-43.
- Clin. Pharmacol. Ther , vol.86 , pp. 32-43
- Lathia, C.D.¹

2
- 67650636515
- US Food and Drug Administration. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (May 1998).
- US Food and Drug Administration. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (May 1998).

3
- 0037534027
- Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval
- Peck, C.C., Rubin, D.B. & Sheiner, L.B. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin. Pharmacol. Ther. 73, 481-490 (2003).
- (2003) Clin. Pharmacol. Ther , vol.73 , pp. 481-490
- Peck, C.C.¹ Rubin, D.B.² Sheiner, L.B.³

4
- 0035037328
- Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies
- Lesko, L.J. & Atkinson, A.J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41, 347-366 (2001).
- (2001) Annu. Rev. Pharmacol. Toxicol , vol.41 , pp. 347-366
- Lesko, L.J.¹ Atkinson Jr., A.J.²

5
- 38349115335
- Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: Impact of FDA pharmacometrics during 2004-2006
- Wang, Y. et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J. Clin. Pharmacol. 48, 146-156 (2008).
- (2008) J. Clin. Pharmacol , vol.48 , pp. 146-156
- Wang, Y.¹

6
- 67650590069
- Actonel product label. Cincinnati, OH: Procter & Gamble.
- Actonel product label. Cincinnati, OH: Procter & Gamble.

7
- 67650634070
- Carvedilol product label. Philadelphia, PA: GlaxoSmithKline
- Carvedilol product label. Philadelphia, PA: GlaxoSmithKline.

8
- 67650634071
- Zosyn product label. Philadelphia, PA: Wyeth
- Zosyn product label. Philadelphia, PA: Wyeth.

9
- 65249191379
- Quantitative disease, drug, and trial models
- Gobburu, J.V. & Lesko, L.J. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49, 291-301 (2009).
- (2009) Annu. Rev. Pharmacol. Toxicol , vol.49 , pp. 291-301
- Gobburu, J.V.¹ Lesko, L.J.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.